

Subject information					
Subject Study Number _ _ _ Age: _					
All Serious Adverse Events must be reported within 24 hours after onset. Please email the SAE to: savefgr@amsterdamumc.nl					
A follow up report must be sent within 7 days and fina	al report when outcome of SAE is known				
Investigator Information					
Local Investigator :	al Investigator : Site:				
mail: Phone:					
Date of Report (Follow up reports can be completed in this initial report)					
Initial// Follow up (FU)/// DD MMM YY	FU / / FU / / YY DD MMM YYYY DD MMM YYYY				
Final// DD	Final// DDMMMYYYY				
Date of awareness SAE // // / DD MMM /YYYY					
Serious Adverse Event Information					
What is the Adverse Event					
Date Onset AE:// Date AE became serious:// DD_MMM_YYYY Date AE resolved:// Date AE resolved://					
Category of SAE:	Status of SAE at time of this report				
□ Death	□ Fatal				
□ Life threatening	□ Completely resolved on// (date)				
□ Hospitalization/prolongation	\Box Resolved with sequelae,/ (date)				
Congenital anomaly/birth defect	□ Not completely resolved:				
Persistent/significant disability	□ ongoing unchanged				
Important medical event	□ ongoing with increased intensity				
	ongoing with decreased intensity				



	FGR YO			
Subject information				
	Age:			
	0			
In case of death	1			
PATIENT	CHILD			
Date of death (if applicable):	Date of death (if applicable):			
<u>Was the patient's death related to study drugs:</u> \Box Yes \Box No.	Was the patient's death related to study drugs: \Box Yes \Box No.			
If yes, please specify:	If yes, please specify:			
Causes of death (listed primary cause of death first):	Causes of death (listed primary cause of death first):			
Serious Adverse Event Information: Provide a brief narra (diagnosis), including:	ative description of the SAE (presenting symptoms			
Diagnosis and symptoms				
Tests and treatment				
Relevant Medical History				

Information of the child

Brief summary

Age: |__|_|

/

Subject information

Signatures:

Investigator printed name

Subject Study Number |__|_|_|_|



/ /

Date (DD/MMM/YYYY)

Relevant concomitant medication: report medication limited to relevant prophylaxis and supportive care and medication that the investigator considers to be possibly contributing to the occurrence of the SAE. Do not report medication given to treat the SAE.						
Drug (generic name)	Dose (units)	Route (iv, po,)	Date first dose (DD/MMM/YYYY)	Date last dose (prior to SAE)		
			//	//		
			//	//		
			//	//		
			//	//		
			//	//		

Investigator signature

	VE FGR YOU
Subject information	
Subject Study Number _ _ Age:	_
To be completed by Staff study team:	
Receipt date of SAE report SAE sequence nu	Imber: SAE III
SAE evaluation has been performed by Staff Member of project team:	
Name:Signature:	Date:
Medical review has been performed by Principle Investigator of study	
Name: Signature:	Date:
Comments by medical reviewer:	
1. Has SAE consequence for safety of subject \Box NO \Box YES which	and any action taken? Specify:
 SAE category: □ related to study treatment of study procedure □ r device □ other, specify, 	elated to medical device \Box related to failure of